Provide feedbackProvide feedback

Home :: Pediatrics :: Pediatrics Conferences :: APA 2007 Annual Meeting - ADHD track

American Psychiatric Association

APA 2007 Annual Meeting - ADHD track

May 19-24, 2007San Diego, CA
VerusMed is an independent news organization and is not affiliated with the American Psychiatric Association

Interpatient pharmacokinetic variability lower in patients receiving lisdexamfetamine as compared with mixed amphetamine salts

Thursday, December 13, 2007 | Comments

An analysis of 17 patients with attention-deficit/hyperactivity disorder who received either lisdexamfetamine dimesylate or an extended-release formulation of mixed amphetamine salts (MAS XR) shows that the interpatient variability of lisdexamfetamine is lower than that of MAS XR.

The study population came from a larger ...[more] Locked

Long-term treatment with lisdexamfetamine safe, effective in children with ADHD

Thursday, December 13, 2007 | Comments

A long-term study of children with attention-deficit/hyperactivity disorder shows that treatment with lisdexamfetamine appears to be safe and effective.

The open-label, single-arm study included 272 children aged 6 to 12 years with the combined and hyperactive/impulsive subtypes of ADHD. Most of the children (n=271) were ...[more] Locked

ADHD associated with high rates of comorbid psychiatric disorders in children, adults of both sexes, studies show

Thursday, December 13, 2007 | Comments

Recent large studies have revealed that attention-deficit/hyperactivity disorder is associated with a host of comorbid psychiatric disorders, according to 3 researchers.

Dr. Joseph Biederman, chief of clinical and research programs in pediatric psychopharmacology and adult ADHD at ...[more] Locked

Interpatient pharmacokinetic variability lower in patients receiving lisdexamfetamine as compared with mixed amphetamine salts

Thursday, December 13, 2007 | Comments

An analysis of 17 patients with attention-deficit/hyperactivity disorder who received either lisdexamfetamine dimesylate or an extended-release formulation of mixed amphetamine salts (MAS XR) shows that the interpatient variability of lisdexamfetamine is lower than that of MAS XR.

The study population came from a larger ...[more] Locked

Long-term treatment with lisdexamfetamine safe, effective in children with ADHD

Thursday, December 13, 2007 | Comments

A long-term study of children with attention-deficit/hyperactivity disorder shows that treatment with lisdexamfetamine appears to be safe and effective.

The open-label, single-arm study included 272 children aged 6 to 12 years with the combined and hyperactive/impulsive subtypes of ADHD. Most of the children (n=271) were ...[more] Locked

Personality characteristics among adults with ADHD dependent on substance use disorder, study shows

Thursday, December 13, 2007 | Comments

Adults with attention-deficit/hyperactivity disorder may have different personality characteristics depending on whether they have a current, prior, or no incidence of substance use disorder (SUD), new data show.

In contrast, adults with autism spectrum disorder (ASD) do not appear to have personality characteristics that ...[more] Locked

Long-term use of methylphenidate transdermal system well tolerated, efficacious in children with ADHD

Thursday, December 13, 2007 | Comments

Long-term treatment with the methylphenidate transdermal system (MTS) is safe and efficacious in children with attention-deficit/hyperactivity disorder, results from a 12-month study show.

The open-label study enrolled children aged 6 to 12 years who had participated in 1 of 4 other studies: a double-blind, 7-week study ...[more] Locked

OROS methylphenidate shows benefits in patients with ADHD who have comorbid mood, anxiety disorders, concomitant drug therapy in trial

Thursday, December 13, 2007 | Comments

The efficacy, safety, and tolerability profile of OROS methylphenidate in adults who have attention-deficit/hyperactivity disorder appears to extend to those who have comorbid depression or anxiety disorders, including those taking concomitant serotonergic uptake inhibitors (SRIs), new findings suggest.

The double-blind ...[more] Locked

Children, adults, patients with substance use disorders can receive appropriate diagnosis, treatment for ADHD

Thursday, December 13, 2007 | Comments

Clinicians can successfully make a diagnosis of and manage attention-deficit/hyperactivity disorder in special groups, such as preschoolers, adults, and patients with substance use disorders, according to a panel of experts.

Dr. Christopher Kratochvil, assistant director of the ...[more] Locked

Extended-release dexmethylphenidate effective in controlling ADHD in children with combined subtype

Thursday, December 13, 2007 | Comments

A post hoc, pooled analysis determined that extended-release formulations of dexmethylphenidate (d-methylphenidate-ER) and d,l-methylphenidate (d,l-methylphenidate-ER) effectively control attention-deficit/hyperactivity disorder symptoms in children with the combined subtype of ADHD. A trend toward efficacy was also seen among ...[more] Locked

Long-term use of methylphenidate transdermal system well tolerated, efficacious in children with ADHD

Thursday, December 13, 2007 | Comments

Long-term treatment with the methylphenidate transdermal system (MTS) is safe and efficacious in children with attention-deficit/hyperactivity disorder, results from a 12-month study show.

The open-label study enrolled children aged 6 to 12 years who had participated in 1 of 4 other studies: a double-blind, 7-week study ...[more] Locked

Personality characteristics among adults with ADHD dependent on substance use disorder, study shows

Thursday, December 13, 2007 | Comments

Adults with attention-deficit/hyperactivity disorder may have different personality characteristics depending on whether they have a current, prior, or no incidence of substance use disorder (SUD), new data show.

In contrast, adults with autism spectrum disorder (ASD) do not appear to have personality characteristics that ...[more] Locked

Children, adults, patients with substance use disorders can receive appropriate diagnosis, treatment for ADHD

Thursday, December 13, 2007 | Comments

Clinicians can successfully make a diagnosis of and manage attention-deficit/hyperactivity disorder in special groups, such as preschoolers, adults, and patients with substance use disorders, according to a panel of experts.

Dr. Christopher Kratochvil, assistant director of the ...[more] Locked

OROS methylphenidate shows benefits in patients with ADHD who have comorbid mood, anxiety disorders, concomitant drug therapy in trial

Thursday, December 13, 2007 | Comments

The efficacy, safety, and tolerability profile of OROS methylphenidate in adults who have attention-deficit/hyperactivity disorder appears to extend to those who have comorbid depression or anxiety disorders, including those taking concomitant serotonergic uptake inhibitors (SRIs), new findings suggest.

The double-blind ...[more] Locked

Extended-release dexmethylphenidate effective in controlling ADHD in children with combined subtype

Thursday, December 13, 2007 | Comments

A post hoc, pooled analysis determined that extended-release formulations of dexmethylphenidate (d-methylphenidate-ER) and d,l-methylphenidate (d,l-methylphenidate-ER) effectively control attention-deficit/hyperactivity disorder symptoms in children with the combined subtype of ADHD. A trend toward efficacy was also seen among ...[more] Locked

Transdermal methylphenidate effectively treats ADHD, improves quality of life in children who switch from ER methylphenidate, research reveals

Thursday, December 13, 2007 | Comments

The methylphenidate transdermal system (MTS) is a safe and effective treatment for children with attention-deficit/hyperactivity disorder, new study findings indicate. Study data also suggest treatment with MTS may reduce the impact of ADHD on both the child and his or her family relative to treatment with oral, extended-release ...[more] Locked

Abuse risk lower with long-acting stimulants than with short-acting stimulants, data show

Thursday, December 13, 2007 | Comments

Use of long-acting stimulants in the treatment of attention-deficit/hyperactivity disorder is associated with less risk of abuse as compared with use of short-acting ADHD drugs, according to new survey results.

The survey was designed to analyze the risk of abuse of common ADHD treatments. The current analysis included ...[more] Locked

Atomoxetine reduces ADHD symptoms, heavy drinking events in adults with ADHD, alcoholism, findings suggest

Thursday, December 13, 2007 | Comments

Among adults with attention-deficit/hyperactivity disorder and comorbid alcohol abuse, atomoxetine seems to effectively reduce both ADHD symptoms and cumulative heavy drinking events, data suggest.

The double-blind, placebo-controlled study enrolled 147 adults who met DSM-IV-TR criteria for ADHD and alcohol abuse. ...[more] Locked

Experts highlight cognitive symptoms of ADHD, efficacy of available treatments

Thursday, December 13, 2007 | Comments

In addition to behavioral symptoms, attention-deficit/hyperactivity disorder is also associated with cognitive deficits, but currently available pharmacotherapies for ADHD can successfully treat many of the disorder's cognitive symptoms, according to experts.

Ronna Fried, director of paradigm development at ...[more] Locked

Abuse risk lower with long-acting stimulants than with short-acting stimulants, data show

Thursday, December 13, 2007 | Comments

Use of long-acting stimulants in the treatment of attention-deficit/hyperactivity disorder is associated with less risk of abuse as compared with use of short-acting ADHD drugs, according to new survey results.

The survey was designed to analyze the risk of abuse of common ADHD treatments. The current analysis included ...[more] Locked

Atomoxetine reduces ADHD symptoms, heavy drinking events in adults with ADHD, alcoholism, findings suggest

Thursday, December 13, 2007 | Comments

Among adults with attention-deficit/hyperactivity disorder and comorbid alcohol abuse, atomoxetine seems to effectively reduce both ADHD symptoms and cumulative heavy drinking events, data suggest.

The double-blind, placebo-controlled study enrolled 147 adults who met DSM-IV-TR criteria for ADHD and alcohol abuse. ...[more] Locked

Experts highlight cognitive symptoms of ADHD, efficacy of available treatments

Thursday, December 13, 2007 | Comments

In addition to behavioral symptoms, attention-deficit/hyperactivity disorder is also associated with cognitive deficits, but currently available pharmacotherapies for ADHD can successfully treat many of the disorder's cognitive symptoms, according to experts.

Ronna Fried, director of paradigm development at ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos